Testing a vaccine to prevent gonorrhea infections.
Efficacy of immunization with 4C-MenB in preventing experimental urethral infection with Neisseria gonorrhoeae.
This study is looking at how well the 4C-MenB vaccine can help protect people from gonorrhea, a sexually transmitted infection that is becoming harder to treat, by seeing how it boosts the immune system to fight off the bacteria.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-11086812 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of the 4C-MenB vaccine in preventing infections caused by Neisseria gonorrhoeae, a sexually transmitted bacterium that is increasingly resistant to antibiotics. Using a unique human experimental infection model, the study aims to understand how the vaccine can stimulate immune responses to protect against gonorrhea. Participants will receive the vaccine and be monitored for its ability to prevent infection, providing valuable insights into potential new prevention strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are sexually active individuals, particularly men, who are at risk for gonorrhea infections.
Not a fit: Patients who are not sexually active or those who have already been diagnosed with gonorrhea may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that significantly reduces the incidence of gonorrhea infections, particularly those that are antibiotic-resistant.
How similar studies have performed: Previous vaccination campaigns against related bacteria have shown success in reducing gonorrhea rates, suggesting that this approach may be promising.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Duncan, Joseph a — Univ of North Carolina Chapel Hill
- Study coordinator: Duncan, Joseph a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.